immunogenicity of yellow fever vaccine in a pediatric population vaccinated at 12-23 months of age in argentina

Conditions: Yellow Fever

Summary: northern argentina is a risk area for yellow fever (yf). recent studies have suggested that immunity wanes in children vaccinated between 9 and 23 months of age. in 2015, a collaborative study conducted by the ministry of health (moh) of argentina, the pan american health organization (paho), and the us centers for disease control and prevention (cdc) assessed the immunogenicity and safety of co-administration of yf and mmr vaccines in a pediatric population at 12-13 months of age. a total of 741 children presenting for routine immunization at 12-13 months of age enrolled and completed the study. it is now four to seven years since this pediatric group received their yf vaccinations. this cohort is unique because their initial yf vaccination and immune response to the vaccine dose are well characterized. contact information collected during the earlier study will be used to locate the children. if consent is obtained, a 5ml specimen of blood will be collected and shipped to the cdc's arboviral diseases reference laboratory (adrl) in fort collins, co for plaque reduction neutralization testing using a 50% cut-off (prnt50) to detect yf virus-specific neutralizing antibodies. children with neutralizing antibody titers that are higher than their baseline titer collected approximately 28 days following yf vaccination will have prnts done for cross-reacting flaviviruses.

yellow fever (yf) continues to be a public health problem for 13 countries in the americas, including northern argentina. from 1960 to 2019, these countries reported 9,673 confirmed cases and 2,480 deaths. in the same period, argentina reported 69 confirmed cases with two deaths. vaccination against yf is recommended for all children living in risk areas in the americas. in argentina, the vaccine was administered at the same visit as the measles, mumps, and rubella (mmr) vaccine at 12 months of age. a study published in 2011 found that simultaneous vaccination with yf and mmr vaccines had a negative impact on yf, mumps, and rubella seroconversion rates in brazilian children aged 12 to 23 months. in 2013, the strategic advisory group of experts (sage) on immunization reviewed the available data on the co-administration of the yf vaccine with other inactivated and lived attenuated vaccines. in its june 2013 position paper, the who states that the yf vaccine can be co-administered with other vaccines but recommends further studies on co-administration with other vaccines, including mmr. in 2013, the ministry of health of argentina changed the indication age for the yf vaccine to be administered to the pediatric population of 18 months, given concerns about a possible interference with mmr and the number of additional vaccines recommended for the pediatric population of 12 months. in 2015, a collaborative study between the ministry of health (moh) of argentina, the pan american health organization (paho), and the us centers for disease control and prevention (cdc) was initiated to assess the immunogenicity and the safety of joint administration of the yf and mmr vaccines in the pediatric population vaccinated at 12-13 months of age. 741 children presenting for routine immunization at 12-13 months of age enrolled and completed the study. three randomized groups received the yf and mmr vaccines simultaneously or 28 days apart. the study found high seroconversion rates against all antigens in the co-administered and sequential groups. however, the magnitude of the antibody response was lower for yf, rubella, and mumps when the vaccines were co-administered. the who currently states that a single dose of the yf vaccine is sufficient to confer lifelong sustained protective immunity against the disease; a booster dose is unnecessary. however, since the booster dose requirement was removed in 2013, new data have been published from pediatric population cohorts in brazil, mali, and ghana, indicating a decrease in the proportion of children seropositive for neutralizing antibodies over time. seropositivity rates as low as 28% for children in ghana have been reported two years after vaccination. given these findings, who and paho have prioritized obtaining additional longer-term immunogenicity data for the pediatric population vaccinated against yf. the children who participated in the argentina yf and mmr vaccination study provide an opportunity to assess whether the argentine childhood immunization program provides adequate long-term immunity against yf. the last minor enrolled in 2018; it has been four to seven years since this pediatric group received their regular yf vaccinations. this cohort is unique because their initial yf vaccination and immune response to the vaccine dose are well characterized. this program evaluation is necessary to provide argentina with evidence to inform future changes to its childhood immunization schedule. contact information collected during the co-administration study will be used to locate the children who completed the study. if consent is obtained, a 5ml specimen of blood will be collected and shipped to the cdc's arboviral diseases reference laboratory (adrl) in fort collins, co for plaque reduction neutralization testing using a 50% cut-off (prnt50) to detect yf virus-specific neutralizing antibodies. children with neutralizing antibody titers that are higher than their baseline titer collected approximately 28 days following yf vaccination will have prnts done for cross-reacting flaviviruses.

Eligibility criteria:
inclusion criteria: * children enrolled in the 2015 study received one dose of yf vaccine and had documented seroconversion regardless of the * healthy child, determined by clinical history * availability to perform a single blood draw * informed consent signed by the parents. exclusion criteria: children in the 2015 study received one dose of the yellow fever vaccine and had no documented seroconversion. * children enrolled in the 2015 study received a dose of the yellow fever vaccine and had documented seroconversion but, for different reasons, received a booster (minimum interval of one month between doses). * children enrolled in the 2015 study received one dose of the yellow fever vaccine and had documented seroconversion but developed yellow fever * children enrolled in the 2015 study received one dose of the yellow fever vaccine and had documented seroconversion but are participating in another clinical drug trial of a drug, vaccine, or medical device * children enrolled in the 2015 study received a dose of the yellow fever vaccine and had documented seroconversion but, for various reasons, are immunocompromised: weakened immune function, including hiv infection, primary immunodeficiencies, having received immunosuppressive doses of oral or injectable corticosteroids (or equivalent), having received immunomodulators or chemotherapeutic agents, disease of the thymus, severe illness/fever (mild illness without fever is not an exclusion criteria) ● any condition that, in the judgment of study personnel, poses a risk to the health of the participant or interferes with the assessment of response to the vaccine

Keywords: antibodies response yellow fever vaccine